TUBB2B: A Potential Drug Target and Biomarker for Turbin-Inhibitors

Target Name: TUBB2B

NCBI ID: G347733

TUBB2B

TUBB2B: A Potential Drug Target and Biomarker for Turbin-Inhibitors

Introduction

Tubulin, the protein subunit of microtubules, plays a critical role in cell division, intracellular transport, and other life activities. The beta-tubulin protein is a paralog, which means that it has similar sequence but with a different arrangement of amino acids.TUBB2B is a specific beta-tubulin paralog that is expressed in human tissues and has been identified as a potential drug target and biomarker for turbin inhibitors.

During the cell division cycle, tubulin helps to maintain the integrity of the microtubules, which are essential for proper cell division and transport of organelles. In addition, tubulin also plays a role in the regulation of cell shape and the transport of vesicles within the cell.

TUBB2B is a 21-kDa protein that is expressed in various human tissues, including muscle, heart, brain, and kidney. It is localized to the cytoplasm and is involved in the regulation of cell shape, cytoskeleton organization, and intracellular transport. TUBB2B has has been shown to play a role in the regulation of mitochondrial dynamics and in the modulation of cellular metabolism.

TUBB2B is also a potent inhibitor of the protein kinesin, which is a key regulator of mitochondrial transport. Kinesin is a transmembrane protein that plays a role in the regulation of mitochondrial fusion, which is critical for the delivery of oxygen and nutrients to the cells.

TUBB2B inhibition has been shown to result in a decrease in mitochondrial fusion and an increase in the delivery of oxygen and nutrients to the cells. This has potential implications for the treatment of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

As a potential drug target, TUBB2B is an attractive target for small molecule inhibitors, including those that target the kinesin-associated protein (KAP) domain. KAP is a critical region of kinesin that is involved in the regulation of mitochondrial fusion, and is a target for several anti-cancer drugs.

In addition to its potential as a drug target, TUBB2B also has potential as a biomarker for the diagnosis and monitoring of various diseases. For example, TUBB2B has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer . This suggests that it may be a useful biomarker for the diagnosis and monitoring of these diseases.

Conclusion

TUBB2B is a unique and highly promising protein that has been identified as a potential drug target and biomarker for turbin inhibitors. Its role in the regulation of cell division, cytoskeleton organization, and intracellular transport, as well as its potent inhibition of the protein kinesin, make it an attractive target for small molecule inhibitors.

Furthermore, TUBB2B has been shown to be expressed in various types of cancer, which makes it a potential biomarker for the diagnosis and monitoring of these diseases. Therefore, TUBB2B is a promising target for small molecule inhibitors and a potential drug target for the treatment of various diseases.

Protein Name: Tubulin Beta 2B Class IIb

Functions: Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers (PubMed:23001566, PubMed:28013290, PubMed:26732629). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin. Plays a critical role in proper axon guidance in both central and peripheral axon tracts (PubMed:23001566). Implicated in neuronal migration (PubMed:19465910)

The "TUBB2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUBB2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets